← Leaderboards
Bruce H Horwitz
Brigham And Women'S Hospital
$3,653,470
Attributed
$5,697,351
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $822K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,697,351 · 3
By mechanism
R01$5,604,101 · 2
P30$93,250 · 1
Top collaborators
- Gill Diamond5 shared
- Sarah C Glover5 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Michael R Wessels$15,732,288
- Stephanie A Shore$11,152,764
- Xuehong Zhang$8,853,123
- Jamil Azzi$5,263,824
- Tanya N. Mayadas$28,624,599
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoT-LymphocyteImmuneInflammatoryGenesCellsResponseInflammatory ResponsePathway InteractionsDefectInterferonsRegulationProductionGene ExpressionExhibitsPlayPathogenNovel TherapeuticsPathogenesisInsightMucous MembraneInfectionCytokineInflammation
Grant awards (15)
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway$741,811
R01 · FY2025 · DE
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway$737,561
R01 · FY2024 · DE
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway$764,413
R01 · FY2023 · DE
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway$1
R01 · FY2023 · DE
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway$822,036
R01 · FY2022 · DE
Inhibition of Microflora-Induced Colitis by NF-kB$440,400
R01 · FY2010 · AI · contact PI
Inhibition of Microflora-Induced Colitis by NF-kB$458,755
R01 · FY2009 · AI · contact PI
Inhibition of Microflora-Induced Colitis by NF-kB$351,254
R01 · FY2007 · AI · contact PI
Inhibition of Microflora-Induced Colitis by NF-kB$361,745
R01 · FY2006 · AI · contact PI
PF # 3: Regulation of Cutaneous Inflammation by Inhibitory NF-kB Subunits (Bru$25,000
P30 · FY2006 · AR · contact PI
Inhibition of Microflora-Induced Colitis by NF-kB$370,450
R01 · FY2005 · AI
PF # 3: Regulation of Cutaneous Inflammation by Inhibitory NF-kB Subunits (Bru$25,000
P30 · FY2005 · AR
Inhibition of Microflora-Induced Colitis by NF-kB$370,450
R01 · FY2004 · AI
PF # 3: Regulation of Cutaneous Inflammation by Inhibitory NF-kB Subunits (Bru$43,250
P30 · FY2004 · AR
Inhibition of Microflora-Induced Colitis by NF-kB$185,225
R01 · FY2003 · AI